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ABSTRACT
Background Amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD) are progressive
neurodegenerative disorders that share signiﬁcant clinical,
pathological and genetic overlap and are considered to
represent different ends of a common disease spectrum.
Mutations in Proﬁlin1 have recently been described as a
rare cause of familial ALS. The PFN1 E117G missense
variant has been described in familial and sporadic cases,
and also found in controls, casting doubt on its
pathogenicity. Interpretation of such variants represents a
signiﬁcant clinical-genetics challenge.
Objective and results Here, we combine a screen of a
new cohort of 383 ALS patients with multiple-sequence
datasets to reﬁne estimates of the ALS and FTD risk
associated with PFN1 E117G. Together, our cohorts add
up to 5118 ALS and FTD cases and 13 089 controls. We
estimate a frequency of E117G of 0.11% in controls and
0.25% in cases. Estimated odds after population
stratiﬁcation is 2.44 (95% CI 1.048 to∞, Mantel-
Haenszel test p=0.036).
Conclusions Our results show an association between
E117G and ALS, with a moderate effect size.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating
neurodegenerative disorder in which the progres-
sive loss of motor neurons causes weakness and
paralysis leading to death typically 3–5 years after
onset.1 Around 5–10% of ALS cases are familial,
which has allowed the identiﬁcation of a handful of
mutant genes that cause classical dominant
adult-onset ALS, and are occasionally found in
sporadic patients with ALS, who report no family
history for the disease.2 Frontotemporal dementia
(FTD) co-occurs in 5–10% of patients with ALS
and the ﬁnding that a number of mutations can
cause either disorder, and that ALS and FTD post-
mortem pathology observations share numerous
similarities, has led to these disorders being consid-
ered part of the same disease spectrum.3
Recently, Wu et al4 have identiﬁed missense
mutations in Proﬁlin 1 (PFN1), a three-exon gene
encoding a protein involved in actin ﬁlament for-
mation, as causative of ALS. With the exception of
the E117G mutation, all mutant PFN1 alleles were
found in familial ALS cases. One successive study
identiﬁed a novel missense mutation, while a
number of screening studies have failed to identify
mutations, suggesting these are a rare cause for
ALS. By contrast, the E117G mutation was identi-
ﬁed in control and familial cases, and was also
found at a lower frequency in controls in other
populations, thus casting a doubt on the signiﬁ-
cance of this variant.5–11
Here we report the screening of a UK population
for PFN1 mutations. We identify cases carrying the
E117G variant and analyse the frequency of this
variant in 4700 UK controls. We then meta-analyse
all the published and publicly available data for this
variant, to conclude this may represent a rare risk
factor for ALS.
METHODS
Study population
Three hundred and eighty-three sporadic and
familial ALS cases, from specialist motor neuron
disease clinics in London, UK, (UCL Partners
motor neuron disease clinics), provided written
informed consent. The familial cases were 23 and
represent 6% of the cohort. DNA was extracted
from whole blood.
Sequencing analysis
PFN1 exons 1, 2 and 3 were subjected to PCR
ampliﬁcation by REDtaq Polymerase (Sigma), using
the primers and PCR conditions as described in Wu
et al.4 Reaction mixtures were made up in accord-
ance with the manufacturer’s instructions. The
PCR product was puriﬁed from the ampliﬁcation
mixture using microCLEAN PCR clean-up kit
(Microzone), and the repeat region of interest was
sequenced using ABI Prism BigDye Terminator
Cycle Sequencing Ready Reaction kit V.1.1. 15 mL
sequencing reactions comprised of 5–20 ng of
DNA template, 1 mL BigDye mix, 5 mL Better
Buffer (Microzone), 5 pmol of the forward and
reverse sequencing primer (same as PCR primers),
1 mL betaine and were made up with an appropri-
ate volume of nuclease-free water. Cycling para-
meters for sequencing were set to 300 s at 95°C,
30 s denaturing at 96°C, 15 s annealing at 55°C,
240 s extension at 60°C and repeated for 35 cycles.
Sequences were precipitated in ethanol, EDTA and
sodium acetate solution and further washed in 70%
ethanol. Sequences were determined on a 3730xl
DNA Analyser capillary sequencer (Applied
Biosciences) and analysed with Geneious V.6.1
sequencing software (Biomatters).
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Search of public databases and published data
We searched for published sequencing data on PFN1 in ALS,
FTD and control cases from prevalently Caucasian cohorts,
updated to 10 May 2013. In particular, we received from the
UK10K, (http://www.uk10k.org, a large sequencing study of UK
individuals with conditions not related to ALS/FTD) the allele
frequency for E117G in 4732 exome sequences.
Statistical methods
Association p values were based on Fisher exact tests using the
allele count data. Stratiﬁed population analysis was performed
using the stratiﬁed Mantel–Haenszel test. All tests were per-
formed using the R statistical software.
RESULTS
Sequence screening of PFN1 in a UK ALS cohort
Screening of the three PFN1 exons in our samples revealed no
novel variant. We identiﬁed two ALS samples carrying the
dinucleotide substitution leading to the previously described
E117G coding change. Both patients had no ALS family history.
The ﬁrst patient was a male with bulbar onset ALS, age was 65
years at onset, and a very slowly progressive form of disease.
The second patient was a male with limb onset ALS, age was 54
years at onset, and a disease duration of 3 years. Both patients
were negative for screening of C9orf72 expansions and muta-
tions in TARDBP, FUS and VCP.
Meta-analysis of PFN1 E117G variant
To estimate the frequency of the E117G alleles in controls, we
combined several publicly available cohorts of exome-sequenced
individuals, whose conditions do not overlap with the ALS-FTD
spectrum. The largest control cohorts are: NHLBI
Exome-sequencing dataset (4300 European–American samples),
and the UK10K dataset (4732 UK samples).
We then collected all the published and publicly available data
on the E117G PFN1 variant in ALS and FTD. Combining all
cohorts, we obtained information on 5118 cases and 13 089
controls of prevalently European descent.
We initially performed our statistical analysis using the ori-
ginal discovery set from Wu et al,4 with the following modiﬁca-
tions to the control group: (A) we excluded the 1K Genome
Project data due to low coverage and potential shortfall in
detecting rare variants; (B) we excluded the African–American
samples from the Exome Variant Server, since the E117G muta-
tion appears to be speciﬁc to European-descent populations;
(C) we updated the European-descent samples as on June 2013.
This analysis shows an OR=3.71 (Fisher exact test p=0.098)
(table 1).
We then analysed all available datasets which included cases
and controls (total of 4024 cases and 8777 controls) and took
into account population stratiﬁcation by using a Mantel–
Haenszel test. This analysis showed a signiﬁcant difference
between groups (p=0.036) and an OR of 2.22 (1.1 to ∞ 95%
one-tailed CI) (table 1).
By combining all available data, also from non-case-control
studies, the variant was present in 13 out of 5118 cases and 15
out of 13 089 control samples conferring similar results to the
Mantel–Haenszel test, and showing an OR=2.22 (95% CI 1.1
to ∞ Fisher exact test p=0.036) (table 1).
DISCUSSION
PFN1 mutations have been reported to be a rare cause of familial
ALS.4 7 The PFN1 E117G variant has been also found in spor-
adic ALS patients, but its presence in numerous control indivi-
duals has raised concerns about its role in disease.4–11 With the
recent advances in DNA sequencing technologies, information
on one patient’s whole exome or multiple candidate genes is
quickly obtainable—in this context, the interpretation of var-
iants, such as PFN1 E117G, becomes an important clinical-
genetics challenge.
In a new screen of 383 UK patients with ALS, we found two
E117G carriers. No novel variant was found. In order to gain
insight as to how to interpret the role of this variant, we
Table 1 Frequency of PFNI E117G variant
Population ALS E117G FTD E117G
TOTAL
cases E117G CONTROL E117G p Value
OR (one-tailed
95% CI) Reference
Original discovery set (after exclusion of African samples in NHLBI dataset, and removal of 1000 genomes cohort)
North American* 1090 3 1090 3 1089 1 4
European American 4300 3 NHLBI exome
sequencing project
Total 1090 3 5389 4 0.098 3.71
Validation datasets
UK* 383 2 383 2 4732 8 UK10K (http://www.
uk10k.org)
US/Nordic/German* 672 1 16 0 688 1 972 0 7
French 46 0 119 0 165 0 8
Italian* 1168 1 203 0 1371 1 1132 0 9
Canadian 94 0 94 0 5
Australian 825 3 825 3 11
Belgian* 174 0 328 3 502 3 864 3 6
Combined analysis
Total (all samples, not
stratified)
4452 10 666 3 5118 13 13 089 15 0.036 2.22 (1.1 to ∞)
Total* (stratified Mantel–
Haenszel test)
4024 10 8777 12 0.038 2.44 (1.048 to ∞)
*Indicates case-control datasets used for the Mantel–Haenszel test.
ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia.
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performed an analysis on all publicly available data for the
E117G variant, and we ﬁnd consistent evidence for the associ-
ation between E117G and ALS andFTD (p=0.036), with an
estimated OR of 2.44 (95% CI 1.048 to ∞ p=0.038).
Wu et al4 performed functional studies on ﬁve PFN1 muta-
tions, including the E117G variant, demonstrating an effect on
protein aggregation, actin binding and axon outgrowth. The
E117G variant generally showed intermediate results between
the wild-type and the other mutations, reaching signiﬁcant dif-
ferences from the wild-type in protein aggregate formation and
in increased levels in insoluble protein fractions. Axon out-
growth inhibition was observed, but did not reach statistical sig-
niﬁcance, and actin binding appeared to be normal.4 In
summary, functional characterisation of the E117G variant
shows lesser changes than clear PFN1 pathogenic mutations, but
supports a possible role as risk factor for ALS.
The possibility of multiple mutations contributing to ALS in
one individual,12 and the role of rare variants in complex dis-
eases such as ALS and FTD, remains to be elucidated and will
require very large cohorts in order to obtain sufﬁciently convin-
cing results. Recently, Geschwind and collaborators have shown
that a rare variant in the MAPT gene, where mutations are
known to be causative for FTD, can act as a risk factor for FTD
and Alzheimer’s disease.13 Similarly, we here suggest that a rare
variant in PFN1, a gene in which mutations are known to be
causative for ALS, can act as a risk factor for disease.
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